Among patients who did receive early DNAR orders, survival to hospital discharge did not differ by race or ethnicity.

Recent findings support the use of EHRs not only for individual patient care but also for family-centered interventions to curb the growing diabetes epidemic.

Patients undergoing lung or colon cancer surgery at rural hospitals that later closed had better outcomes after transfer to high-performing oncology centers.

Last week, OpenAI launched AI tools for health care organizations, including ChatGPT for Healthcare, designed to improve care and streamline administrative tasks.

Nursing home capacity has declined since the COVID-19 pandemic, causing greater strain on postacute care, especially in rural areas.

A recent study reveals that medical debt significantly increases the risk of housing instability, highlighting urgent implications for health policy and financial security.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

Roy Mathew, MD, discusses integrating nephrology and cardiology to bridge the gap in patient adherence and care delivery.

This analysis of more than 250,000 adults at least 50 years old with chronic conditions showed lower portal use among older, non–English-speaking, and Black patients, underscoring digital health equity gaps.

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.

Dani Castillo, MD, sheds light on the evolving landscape of first-line therapy in advanced gastric cancer.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.